Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Taiho Pharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04587908CT.gov A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） | — | Active Not Recruiting | — | — | — |
NCT02752048CT.gov A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | — | Completed | — | — | — |
NCT02246478CT.gov A Study of TAS-205 for Duchenne Muscular Dystrophy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Duchenne Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tas-205 (this asset) | Taiho Pharmaceutical Co., Ltd. | P3 | BB · 66 |
| Viltolarsen | NS Pharma, Inc. | P4 | BBB |
| Delandistrogene Moxeparvovec | Sarepta Therapeutics, Inc. | P3 | BB |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | BB |
| Golodirsen | Rare Disease Research, LLC | P4 | BB |
| Eteplirsen | Sarepta Therapeutics, Inc. | P3 | BB |
| Glutamine | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Prednisolone | Anne M. Connolly | P4 | BB |
| Casimersen | Kevin Flanigan | P3 | BB |
+41 more in the Duchenne Muscular Dystrophy cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tas-205 in Duchenne Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tas-205-duchenne-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →